SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2a1a'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ONI_I_BEZI517_0 (14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 7	TYR B 454 ILE B 378 PHE B 494 ALA B 479	None	1.06A	1oniG-2a1aB: undetectable 1oniI-2a1aB: undetectable	1oniG-2a1aB: 18.28 1oniI-2a1aB: 18.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QVU_A_PRLA196_0 (TRANSCRIPTIONAL REGULATOR QACR)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 6	LEU B 374 GLU B 375 THR B 451 TYR B 454	None	1.43A	1qvuA-2a1aB: undetectable	1qvuA-2a1aB: 22.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1SV9_A_DIFA701_1 (PHOSPHOLIPASE A2)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 8	LEU B 474 ILE B 420 GLY B 401 HIS B 406	None	0.78A	1sv9A-2a1aB: undetectable	1sv9A-2a1aB: 21.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_2 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 7	ILE B 273 LYS B 296 LEU B 312 ILE B 320	None	0.81A	1uwjA-2a1aB: 21.9	1uwjA-2a1aB: 31.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2OTF_A_2TNA201_1 (PHOSPHOLIPASE A2 VRV-PL-VIIIA)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 5	LEU B 474 ILE B 420 GLY B 401 HIS B 406	None	0.95A	2otfA-2a1aB: undetectable	2otfA-2a1aB: 21.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B6H_A_MXDA551_1 (PROSTACYCLIN SYNTHASE)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 6	TYR B 472 ALA B 473 LEU B 476 THR B 451	None	0.83A	3b6hA-2a1aB: undetectable	3b6hA-2a1aB: 20.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B6H_B_MXDB551_1 (PROSTACYCLIN SYNTHASE)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 6	TYR B 472 ALA B 473 LEU B 476 THR B 451	None	0.82A	3b6hB-2a1aB: undetectable	3b6hB-2a1aB: 20.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 10	VAL B 281 LYS B 296 VAL B 321 ILE B 364 PHE B 368	None	0.58A	3cs9A-2a1aB: 21.4	3cs9A-2a1aB: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3KW4_A_TICA600_1 (CYTOCHROME P450 2B4)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 11	PHE B 421 ILE B 273 VAL B 294 VAL B 281 GLY B 274	None	0.91A	3kw4A-2a1aB: undetectable	3kw4A-2a1aB: 22.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 6	VAL B 281 LYS B 296 VAL B 321 ILE B 364	None	0.64A	3mssD-2a1aB: 21.2	3mssD-2a1aB: 25.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	ILE B 273 VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 434	None	1.06A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	ILE B 273 VAL B 281 LYS B 296 CYH B 369 PHE B 421 PHE B 433	None	0.96A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	ILE B 273 VAL B 281 LYS B 296 LEU B 312 PHE B 421 PHE B 433	None	1.22A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ONN_A_ACTA271_0 (PROTEIN SSM1)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 5	GLY B 279 GLU B 335 GLY B 276 PRO B 334	None	1.10A	3onnA-2a1aB: undetectable	3onnA-2a1aB: 22.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3P4W_A_DSFA319_1 (GLR4197 PROTEIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 9	ILE B 430 ILE B 420 VAL B 402 TYR B 454 ILE B 477	None	1.29A	3p4wA-2a1aB: 2.1	3p4wA-2a1aB: 23.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WAR_A_NIOA401_1 (CASEIN KINASE II SUBUNIT ALPHA)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 8	VAL B 281 VAL B 294 LYS B 296 ASP B 432	None	0.35A	3warA-2a1aB: 22.7	3warA-2a1aB: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	LYS B 296 ILE B 364 MET B 366 ASN B 419 ASP B 432 PHE B 433	None	1.31A	4lmnA-2a1aB: 21.4	4lmnA-2a1aB: 26.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4PO0_A_NPSA602_1 (SERUM ALBUMIN)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 8	LYS B 304 ALA B 305 GLY B 434 LEU B 362	TPO B 446 ( 3.2A) None None None	0.87A	4po0A-2a1aB: undetectable	4po0A-2a1aB: 20.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 12	LYS B 296 ILE B 364 PHE B 421 GLY B 431 PHE B 433	None	0.94A	4rzvA-2a1aB: 21.9	4rzvA-2a1aB: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 431 GLY B 434	None	1.35A	4rzvB-2a1aB: 21.9	4rzvB-2a1aB: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 431 PHE B 433	None	1.01A	4rzvB-2a1aB: 21.9	4rzvB-2a1aB: 30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 10	VAL B 281 GLU B 308 LEU B 315 ILE B 320 VAL B 321 ILE B 430	None	0.75A	4u0iA-2a1aB: 21.3	4u0iA-2a1aB: 29.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	7 / 12	VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 431 ASP B 432 PHE B 433	None	0.89A	4xv2A-2a1aB: 22.1	4xv2A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	LYS B 296 CYH B 369 PHE B 421 GLY B 431 ASP B 432 PHE B 433	None	0.86A	4xv2B-2a1aB: 22.1	4xv2B-2a1aB: 30.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_B_DB8B800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 10	PHE B 368 CYH B 369 GLY B 372 ASP B 432	None	0.43A	5ajqB-2a1aB: 21.5	5ajqB-2a1aB: 26.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 431 PHE B 433	None	0.78A	5cswA-2a1aB: 21.9	5cswA-2a1aB: 30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 12	VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 431 PHE B 433	None	0.82A	5cswB-2a1aB: 21.8	5cswB-2a1aB: 30.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 12	VAL B 281 LYS B 296 ILE B 364 PHE B 421 GLY B 431	None	0.76A	5hieA-2a1aB: 21.6	5hieA-2a1aB: 29.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 12	VAL B 281 LYS B 296 ILE B 364 PHE B 421 GLY B 431	None	0.79A	5hieB-2a1aB: 21.6	5hieB-2a1aB: 29.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 12	VAL B 281 LYS B 296 ILE B 364 PHE B 421 GLY B 431	None	0.76A	5hieD-2a1aB: 21.9	5hieD-2a1aB: 29.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IH0_A_ACTA402_0 (MACROLIDE 2'-PHOSPHOTRANSFERAS E II)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 6	PRO B 417 ARG B 453 THR B 491 ILE B 378	None	1.17A	5ih0A-2a1aB: 8.4	5ih0A-2a1aB: 22.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 7	GLY B 274 GLY B 276 VAL B 281 LYS B 296 ASP B 432	None	0.71A	5j5xA-2a1aB: 23.1	5j5xA-2a1aB: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	6 / 10	VAL B 281 LYS B 296 GLU B 308 ILE B 364 PHE B 368 GLY B 372	None	0.70A	5mo4A-2a1aB: 18.1	5mo4A-2a1aB: 19.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MZR_A_PFLA412_1 (PROTON-GATED ION CHANNEL)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 10	ILE B 430 ILE B 420 VAL B 402 TYR B 454 ILE B 477	None	1.26A	5mzrA-2a1aB: 2.8	5mzrA-2a1aB: 12.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MZR_D_PFLD410_1 (PROTON-GATED ION CHANNEL)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	5 / 9	ILE B 430 ILE B 420 VAL B 402 TYR B 454 ILE B 477	None	1.26A	5mzrD-2a1aB: 2.8	5mzrD-2a1aB: 12.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	7 / 12	GLU B 271 ILE B 273 GLY B 274 GLU B 308 CYH B 369 PHE B 421 ASP B 432	None	1.09A	5vc3A-2a1aB: 25.0	5vc3A-2a1aB: 32.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	7 / 12	ILE B 273 GLY B 274 GLU B 308 CYH B 369 GLY B 372 PHE B 421 ASP B 432	None	0.88A	5vc3A-2a1aB: 25.0	5vc3A-2a1aB: 32.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y9M_A_NIOA401_1 (CASEIN KINASE II SUBUNIT ALPHA')	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 8	VAL B 281 VAL B 294 LYS B 296 ASP B 432	None	0.39A	5y9mA-2a1aB: 21.8	5y9mA-2a1aB: 13.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y9M_X_NIOX401_1 (CASEIN KINASE II SUBUNIT ALPHA')	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 8	VAL B 281 VAL B 294 LYS B 296 ASP B 432	None	0.36A	5y9mX-2a1aB: 21.7	5y9mX-2a1aB: 13.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YF9_B_NIOB401_1 (CASEIN KINASE II SUBUNIT ALPHA')	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 7	VAL B 281 VAL B 294 LYS B 296 ASP B 432	None	0.44A	5yf9B-2a1aB: 21.6	5yf9B-2a1aB: 13.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YWM_X_NIOX403_0 (CASEIN KINASE II SUBUNIT ALPHA')	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	4 / 7	VAL B 281 VAL B 294 LYS B 296 ASP B 432	None	0.45A	5ywmX-2a1aB: 22.1	5ywmX-2a1aB: 13.67

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1ONI_I_BEZI517_0","14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"TYR B 454;ILE B 378;PHE B 494;ALA B 479","None","1.06A","1oniG-2a1aB:undetectable;1oniI-2a1aB:undetectable","1oniG-2a1aB:18.28;1oniI-2a1aB:18.28"],["1QVU_A_PRLA196_0","TRANSCRIPTIONAL REGULATOR QACR","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"LEU B 374;GLU B 375;THR B 451;TYR B 454","None","1.43A","1qvuA-2a1aB:undetectable","1qvuA-2a1aB:22.18"],["1SV9_A_DIFA701_1","PHOSPHOLIPASE A2","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"LEU B 474;ILE B 420;GLY B 401;HIS B 406","None","0.78A","1sv9A-2a1aB:undetectable","1sv9A-2a1aB:21.62"],["1UWJ_A_BAXA1723_2","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"ILE B 273;LYS B 296;LEU B 312;ILE B 320","None","0.81A","1uwjA-2a1aB:21.9","1uwjA-2a1aB:31.07"],["2OTF_A_2TNA201_1","PHOSPHOLIPASE A2 VRV-PL-VIIIA","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"LEU B 474;ILE B 420;GLY B 401;HIS B 406","None","0.95A","2otfA-2a1aB:undetectable","2otfA-2a1aB:21.62"],["3B6H_A_MXDA551_1","PROSTACYCLIN SYNTHASE","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"TYR B 472;ALA B 473;LEU B 476;THR B 451","None","0.83A","3b6hA-2a1aB:undetectable","3b6hA-2a1aB:20.16"],["3B6H_B_MXDB551_1","PROSTACYCLIN SYNTHASE","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"TYR B 472;ALA B 473;LEU B 476;THR B 451","None","0.82A","3b6hB-2a1aB:undetectable","3b6hB-2a1aB:20.16"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"VAL B 281;LYS B 296;VAL B 321;ILE B 364;PHE B 368","None","0.58A","3cs9A-2a1aB:21.4","3cs9A-2a1aB:25.50"],["3KW4_A_TICA600_1","CYTOCHROME P450 2B4","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"PHE B 421;ILE B 273;VAL B 294;VAL B 281;GLY B 274","None","0.91A","3kw4A-2a1aB:undetectable","3kw4A-2a1aB:22.79"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;LYS B 296;VAL B 321;ILE B 364","None","0.64A","3mssD-2a1aB:21.2","3mssD-2a1aB:25.16"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"ILE B 273;VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 434","None","1.06A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"ILE B 273;VAL B 281;LYS B 296;CYH B 369;PHE B 421;PHE B 433","None","0.96A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"ILE B 273;VAL B 281;LYS B 296;LEU B 312;PHE B 421;PHE B 433","None","1.22A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3ONN_A_ACTA271_0","PROTEIN SSM1","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"GLY B 279;GLU B 335;GLY B 276;PRO B 334","None","1.10A","3onnA-2a1aB:undetectable","3onnA-2a1aB:22.05"],["3P4W_A_DSFA319_1","GLR4197 PROTEIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"ILE B 430;ILE B 420;VAL B 402;TYR B 454;ILE B 477","None","1.29A","3p4wA-2a1aB:2.1","3p4wA-2a1aB:23.05"],["3WAR_A_NIOA401_1","CASEIN KINASE II SUBUNIT ALPHA","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;VAL B 294;LYS B 296;ASP B 432","None","0.35A","3warA-2a1aB:22.7","3warA-2a1aB:25.07"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"LYS B 296;ILE B 364;MET B 366;ASN B 419;ASP B 432;PHE B 433","None","1.31A","4lmnA-2a1aB:21.4","4lmnA-2a1aB:26.02"],["4PO0_A_NPSA602_1","SERUM ALBUMIN","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"LYS B 304;ALA B 305;GLY B 434;LEU B 362","TPO B 446 ( 3.2A);None;None;None","0.87A","4po0A-2a1aB:undetectable","4po0A-2a1aB:20.21"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"LYS B 296;ILE B 364;PHE B 421;GLY B 431;PHE B 433","None","0.94A","4rzvA-2a1aB:21.9","4rzvA-2a1aB:30.47"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 431;GLY B 434","None","1.35A","4rzvB-2a1aB:21.9","4rzvB-2a1aB:30.47"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 431;PHE B 433","None","1.01A","4rzvB-2a1aB:21.9","4rzvB-2a1aB:30.47"],["4U0I_A_0LIA1001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;GLU B 308;LEU B 315;ILE B 320;VAL B 321;ILE B 430","None","0.75A","4u0iA-2a1aB:21.3","4u0iA-2a1aB:29.39"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",7,"VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 431;ASP B 432;PHE B 433","None","0.89A","4xv2A-2a1aB:22.1","4xv2A-2a1aB:30.88"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"LYS B 296;CYH B 369;PHE B 421;GLY B 431;ASP B 432;PHE B 433","None","0.86A","4xv2B-2a1aB:22.1","4xv2B-2a1aB:30.88"],["5AJQ_B_DB8B800_1","SERINE\/THREONINE-PROTEIN KINASE 10","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"PHE B 368;CYH B 369;GLY B 372;ASP B 432","None","0.43A","5ajqB-2a1aB:21.5","5ajqB-2a1aB:26.42"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 431;PHE B 433","None","0.78A","5cswA-2a1aB:21.9","5cswA-2a1aB:30.77"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 431;PHE B 433","None","0.82A","5cswB-2a1aB:21.8","5cswB-2a1aB:30.77"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"VAL B 281;LYS B 296;ILE B 364;PHE B 421;GLY B 431","None","0.76A","5hieA-2a1aB:21.6","5hieA-2a1aB:29.54"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"VAL B 281;LYS B 296;ILE B 364;PHE B 421;GLY B 431","None","0.79A","5hieB-2a1aB:21.6","5hieB-2a1aB:29.54"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"VAL B 281;LYS B 296;ILE B 364;PHE B 421;GLY B 431","None","0.76A","5hieD-2a1aB:21.9","5hieD-2a1aB:29.54"],["5IH0_A_ACTA402_0","MACROLIDE 2'-PHOSPHOTRANSFERASE II","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"PRO B 417;ARG B 453;THR B 491;ILE B 378","None","1.17A","5ih0A-2a1aB:8.4","5ih0A-2a1aB:22.87"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"GLY B 274;GLY B 276;VAL B 281;LYS B 296;ASP B 432","None","0.71A","5j5xA-2a1aB:23.1","5j5xA-2a1aB:25.60"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",6,"VAL B 281;LYS B 296;GLU B 308;ILE B 364;PHE B 368;GLY B 372","None","0.70A","5mo4A-2a1aB:18.1","5mo4A-2a1aB:19.76"],["5MZR_A_PFLA412_1","PROTON-GATED ION CHANNEL","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"ILE B 430;ILE B 420;VAL B 402;TYR B 454;ILE B 477","None","1.26A","5mzrA-2a1aB:2.8","5mzrA-2a1aB:12.68"],["5MZR_D_PFLD410_1","PROTON-GATED ION CHANNEL","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",5,"ILE B 430;ILE B 420;VAL B 402;TYR B 454;ILE B 477","None","1.26A","5mzrD-2a1aB:2.8","5mzrD-2a1aB:12.68"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",7,"GLU B 271;ILE B 273;GLY B 274;GLU B 308;CYH B 369;PHE B 421;ASP B 432","None","1.09A","5vc3A-2a1aB:25.0","5vc3A-2a1aB:32.25"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",7,"ILE B 273;GLY B 274;GLU B 308;CYH B 369;GLY B 372;PHE B 421;ASP B 432","None","0.88A","5vc3A-2a1aB:25.0","5vc3A-2a1aB:32.25"],["5Y9M_A_NIOA401_1","CASEIN KINASE II SUBUNIT ALPHA'","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;VAL B 294;LYS B 296;ASP B 432","None","0.39A","5y9mA-2a1aB:21.8","5y9mA-2a1aB:13.67"],["5Y9M_X_NIOX401_1","CASEIN KINASE II SUBUNIT ALPHA'","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;VAL B 294;LYS B 296;ASP B 432","None","0.36A","5y9mX-2a1aB:21.7","5y9mX-2a1aB:13.67"],["5YF9_B_NIOB401_1","CASEIN KINASE II SUBUNIT ALPHA'","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;VAL B 294;LYS B 296;ASP B 432","None","0.44A","5yf9B-2a1aB:21.6","5yf9B-2a1aB:13.67"],["5YWM_X_NIOX403_0","CASEIN KINASE II SUBUNIT ALPHA'","2a1a","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","Homo sapiens",4,"VAL B 281;VAL B 294;LYS B 296;ASP B 432","None","0.45A","5ywmX-2a1aB:22.1","5ywmX-2a1aB:13.67"]]